Sunday, February 5, 2023

POLITICO NIGHTLY: The public health emergency is ending. Covid isn’t.

 

View in browser
 
POLITICO Nightly logo

BY JOANNE KENEN

A medical worker in April of 2020.

A medical worker in April 2020. The Covid-19 public health emergency will officially end in May. | David Dee Delgado/Getty Images

THREAT LEVEL — On May 10, the United States will be under a public health emergency.

On May 11, it won’t.

But the coronavirus that necessitated that government-declared emergency does not have a calendar. This week’s White House announcement that the PHE is winding down won’t transform Covid-19 at the stroke of midnight, like some viral Cinderella.

What it means is that some of the core public health tools to contain the coronavirus — notably free vaccines, free treatment and free testing — will go away.

Few would argue that the threat from the pandemic hasn’t lessened. May 2023 isn’t May 2022, and it’s certainly not May 2020. Between vaccination and infection, or both, the population has considerable immunity against severe disease, at least for now. Science has advanced.

“There’s a big difference in what life is like. It’s fundamentally different, what we know about the disease, our treatment armament, our preventive armament,” said Kedar Mate, the president and CEO of the Institute for Healthcare Improvement, which has helped hospitals navigate the crisis, including programs to boost resiliency of health care providers.

But Mate and others stressed that less threat doesn’t mean no threat. About 500 people are still dying each day. Even in “good times,” before the uptick in cases after the holidays, roughly 300 were dying on typical days. It’s been that way for months. People who are elderly, un or under-vaccinated, or immune compromised are most vulnerable.

At the rate we are going, the death toll this year is likely to be well over 100,000, possibly closer to 200,000. And — even though you hear all the time that Covid is “just like the flu” — that’s considerably higher than the amount of lives lost to flu in a typical year. Flu deaths vary a lot from year to year but only twice in the last century has it exceeded 100,000 .

And Covid also raises the risk of blood clots, stroke, diabetes, heart failure and other dangerous conditions, and that’s not widely appreciated amongst the public. That aftermath is getting a lot less attention than all the bogus reports of “sudden death” from vaccines flooding social media.

For public health workers and health care providers, the normalization of this high death toll is jarring.

“I never thought that a million deaths of Americans would be trivialized,” said Brian Castrucci, head of the health-focused de Beaumont Foundation. But as a society, he noted, we’ve basically decided: emergency over, time to move on.

Castrucci said pandemic response has to be calibrated; treating it like an on-off switch ”just reinforces this misinformation narrative that is out there.” That downplaying of disease, that acceptance of deaths that actually could be prevented, makes him worry not just about the response to Covid “but for everything in the future.”

Congress late last year took steps to blunt the impact of ending the public health emergency — one of them was making sure that Medicare can cover Paxlovid, an oral medication particularly important for older people. Lawmakers also extended some telemedicine provisions. Much of the CDC preparation and surveillance work was funded in separate legislation, apart from the emergency declaration. (For more on how PHE provisions affect individuals, the POLITICO health team has a run-down .)

Congressional Republicans have rejected White House requests for more Covid funding, including proposals to create a program to cover low-income adult vaccination, similar to immunization programs for children.

The lack of free vaccines, medication and testing starting in May will create new challenges.

Poor people, uninsured people — including those who live in conservative states that have resisted expanding Medicaid under Obamacare — and minority communities will be most at risk, said Julie Morita, the executive vice president of the Robert Wood Johnson Foundation and the former public health commissioner of Chicago.

“Exactly the same people who were disproportionately impacted at the beginning of the pandemic will again be more vulnerable,” she said. Disparities that had narrowed will widen; risks of bad outcomes will grow.

Even people who are insured might face copays or deductibles that make tests and treatments a financial burden. (Health plans have to cover vaccines at no charge under the Affordable Care Act’s preventive care rules.)

When the declared emergency ends, the vaccine distribution system will be turned over to the private sector. That means supply might be spotty in areas with low vaccination demand, including rural areas. People who want shots, or tests, may have trouble finding them, said Celine Gounder, an infectious disease specialist and editor at large for public health at Kaiser Health News.

It’s not just individuals who are at risk in the post-PHE era. The health system hasn’t recovered from the last three years, financially or in terms of its effect on the workforce. That leaves it vulnerable to another variant, another surge, or another kind of public threat altogether, said Gounder.

“You’re dealing with a health care and caregiving workforce that is really burned out,” she said. Understaffed nursing homes can’t take in new patients, some of whom end up remaining in hospitals, which in turn backs up emergency departments. “Health care systems are still going to have difficulty coping,” she said.

Even without a formal public health emergency declaration, the next phase of the pandemic could be manageable — if we find the will to manage it, to balance a “return to normal” with an ongoing layer of collective self-defense. Public health surveillance. Health system readiness. And access to vaccines, tests and treatments — particularly for the most vulnerable among us.

Welcome to POLITICO Nightly. Reach out with news, tips and ideas at nightly@politico.com . Or contact tonight’s author on Twitter at @JoanneKenen .

 

STEP INSIDE THE WEST WING : What's really happening in West Wing offices? Find out who's up, who's down, and who really has the president’s ear in our West Wing Playbook newsletter, the insider's guide to the Biden White House and Cabinet. For buzzy nuggets and details that you won't find anywhere else, subscribe today .

 
 
WHAT'D I MISS?

Arkansas Governor Sarah Huckabee Sanders

Arkansas Governor Sarah Huckabee Sanders will give the official Republican response to President Joe Biden's State of the Union next week. | Drew Angerer/Getty Images

— Sarah Huckabee Sanders picked for GOP State of the Union response: The Arkansas governor will deliver the Republican response to President Joe Biden’s State of the Union address next week, GOP congressional leaders announced today. Sanders, the nation’s youngest governor, was elected to the governor’s mansion in Little Rock last November and sworn in early last month. She is the daughter of former Arkansas Gov. Mike Huckabee and spent nearly two years as White House press secretary during the Trump administration.

— House GOP passes first big whip test, ousting Omar: After a flip-flop-filled struggle, the House GOP’s whip operation passed its first major test: booting progressive Rep. Ilhan Omar (D-Minn.) from a prized committee spot. Republican leaders worked for more than a week to secure the votes to pass the resolution, which cited the Minnesota Democrat’s past comments about Israel. The 218-211-1 vote marks the third time since 2021 that a House majority has forcibly removed a member of the opposition party from a committee. Democrats removed Reps. Marjorie Taylor Greene (R-Ga.) and Paul Gosar (R-Ariz.) from their panels during the last Congress over incendiary comments and social media posts they had made concerning fellow lawmakers.

— Pelosi endorses Schiff in California Senate race — if Feinstein doesn’t run: Former Speaker of the House Nancy Pelosi today endorsed Rep. Adam Schiff (D-Calif.) in California’s high-profile Senate primary , backing the former House Intelligence Committee chair but only on the condition that Democratic Sen. Dianne Feinstein opts not to run again. “If Senator Feinstein decides to seek re-election, she has my whole-hearted support. If she decides not to run, I will be supporting House Intelligence Committee Chair Adam Schiff, who knows well the nexus between a strong Democracy and a strong economy,” Pelosi (D-Calif.) said in a statement.

AROUND THE WORLD

DRUG WARS — The EU wants to give European consumers access to more medicines, faster, and for less money — and it’s picking a fight with the pharmaceutical industry in the process, writes Carlo Martuscelli .

A draft plan to overhaul the EU’s pharmaceutical laws — a copy of which has been obtained by POLITICO — would see the European Commission rip up the perks that drugmakers currently enjoy in order to let unbranded rivals enter the market earlier, driving down prices for consumers.

It proposes slashing the amount of time that pharmaceutical companies have to sell their medicines without competition. At the moment in the EU, companies that develop branded medicines have 10 years to sell a new drug unchallenged, after which rivals can launch unbranded “copycat” drugs that quickly drive down prices — and profits.

The EU wants to reduce that period by two years. That means cheaper drugs would be able to enter the market sooner, helping medicines reach more people.

Consumer groups and civil society organizations have broadly welcomed the moves. Ancel·la Santos Quintano, senior health policy officer at the European Consumer Organisation (BEUC), said the proposal was “positive,” and that it would allow patients faster access to innovative treatments.

Big Pharma sees it differently. It argues that Europe is already falling behind the U.S. and China in the race for research and development. Boston, not Berlin, is the destination of choice for ambitious biotechnology startups working on, say, cutting-edge genetic therapies.

Nathalie Moll, the director general at the European Federation of Pharmaceutical Industries and Associations (EFPIA), the lobby group representing the industry in Europe, blasted the proposal. She pointed to the growing gap in pharmaceutical research investment between the U.S. and Europe, which had grown to €25 billion ($27 billion) from where it stood at €2 billion ($2.2 billion) 25 years ago.

“Whether it is naivety, blind optimism or a more conscious decision for Europe to rely on innovation from the U.S. and Asia, everyone should be in no doubt that what we have seen as draft proposed legislation would be extremely damaging to the competitiveness of Europe’s innovative pharma industry,” Moll told POLITICO.

 

JOIN POLITICO ON 2/9 TO HEAR FROM AMERICA’S GOVERNORS: In a divided Congress, more legislative and policy enforcement will shift to the states, meaning governors will take a leading role in setting the agenda for the nation. Join POLITICO on Thursday, Feb. 9 at World Wide Technology's D.C. Innovation Center for The Fifty: America's Governors, where we will examine where innovations are taking shape and new regulatory red lines, the future of reproductive health, and how climate change is being addressed across a series of one-on-one interviews. REGISTER HERE .

 
 
NIGHTLY NUMBER

109

The number of Democrats who joined Republican lawmakers in the House in voting for a resolution that would denounce socialism , with the measure passing 328-86. Fourteen Democrats voted present, while three Democrats and three Republicans did not vote. The resolution was introduced by Rep. Maria Elvira Salazar (R-Fla.) and denounced the “horrors of socialism” while condemning a list of communist dictators, including Vladimir Lenin and Kim Jong Un.

RADAR SWEEP

GIVE IT UP — Amazon founder Jeff Bezos announced in an interview that he intends to give away most of his fortune, which amounts to $120 billion as of January, 2023. As one of the richest people in the world, the announcement raises questions over how he plans to dispense such a large sum of money . Unlike other philanthropists such as Bill and Melinda Gates, who have carved out philanthropic endeavors in topic areas like global health, Bezos has so far given hefty grants in disparate areas including climate and homelessness. And before 2018, Bezos’s lack of charity work was a source of criticism from the press and some activists. The curiosity over Bezos’ philanthropic endeavors also stems from Amazon, which has faced rising scrutiny and raked in massive profits during the peak of the Covid-19 pandemic. While he no longer serves as CEO, as the company’s largest individual shareholder, his fortune depends on the corporation’s revenue. Some activists in philanthropy circles have argued his newly found vision is disjointed, especially when taking the company’s track record on climate change and labor issues into account. Read the full report from Vox’s Whizy Kim on the billionaire’s newfound philanthropic fervor.

PARTING WORDS

Sen. Ted Cruz (R-Texas).

Sen. Ted Cruz (R-Texas). | Scott Olson/Getty Images

CRUZ CONTROL — Ted Cruz’s presidential ambitions were no secret even before he became the first Republican to jump into the 2016 race. As 2024 approaches, though, he’s playing it uncharacteristically cool, writes Marianne LeVine .

The Texas senator isn’t explicitly ruling out another White House run. But asked about his considerations, Cruz described the Senate as “the battlefield right now,” with his seat up next year and a closer margin in his last reelection bid than is typical for the red state.

“I have no doubt that Democrats will dump a whole lot of money into it,” Cruz said in an interview. “In 2018, it was the most expensive Senate race in U.S. history … And there are a lot of national Democrats who want to do everything they can to try to defeat me. I don’t think they’re going to succeed.”

Should Cruz ultimately bow out of a GOP presidential primary, he’ll have plenty of company among fellow senators. Both Sens. Rick Scott (R-Fla.) and Josh Hawley (R-Mo.), also seen as potential 2024 White House contenders, say they plan to run for reelection in their states. And Sen. Tom Cotton (R-Ark.) said he’s also taking a pass on a presidential run.

It’s a notable divergence from 2016, when four Republican senators jumped into the primary. As GOP lawmakers contend with the tricky dynamics of a polarizing former president’s third White House bid, many in their party are also eager to see an alternative candidate — and there’s a growing awareness that a crowded GOP field could clear the way for Donald Trump. Potential presidential candidates are also watching what other prominent GOP figures like Ron DeSantis will do, letting the Florida governor absorb Trump’s early attacks.

Sen. Lindsey Graham (R-S.C.), who recently endorsed Trump and attended a South Carolina campaign rally with him, suggested that Cruz may be among the crew of potential candidates who will make a call after more deeply assessing the former president’s strength, especially among the party base.

Cruz “has a lot of support, he’s a strong conservative voice in the body,” Graham said. “I think he’d be one of the people who will sort of look and see how Trump does and see what happens.”

Did someone forward this email to you?  Sign up here .

 

Follow us on Twitter

Charlie Mahtesian @PoliticoCharlie

Calder McHugh @calder_mchugh

Katherine Long @katherinealong

Ari Hawkins @_AriHawkins

 

FOLLOW US

Follow us on FacebookFollow us on TwitterFollow us on InstagramListen on Apple Podcast
 


POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA





No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Trump Gets MERCILESSLY BOOED Before He Even ARRIVES

  MeidasTouch 2.39M subscribers MeidasTouch host Adam Mockler reports on Donald Trump receiving a chorus of boos upon his tardy arrival ...